Recent Securities Litigations

AcelRx Pharmaceuticals Inc. Common Stock (NASDAQ: ACRX)

Company Name:AcelRx Pharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: ACRX
Class Period Start:03/17/2020
Class Period End (inclusive):02/12/2021

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (ii) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (iii) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.